168 related articles for article (PubMed ID: 21980664)
1. Anti-TNF treatment and miliary tuberculosis in Crohn's disease.
Milenković B; Dudvarski-Ilić A; Janković G; Martinović L; Mijac D
Srp Arh Celok Lek; 2011; 139(7-8):514-7. PubMed ID: 21980664
[TBL] [Abstract][Full Text] [Related]
2. [Development of cervical tuberculous lymphadenitis in a patient with Crohn's disease receiving infliximab despite of chemoprophylaxis with isoniazid].
Ikeue T; Nakagawa A; Furuta K; Morita K; Sugita T; Nishiyama H
Kekkaku; 2011 Nov; 86(11):879-82. PubMed ID: 22250467
[TBL] [Abstract][Full Text] [Related]
3. [Miliary tuberculosis in a patient with Crohn's disease].
Ferrer I; Maroto N; Montón C; Villagrasa R; López A; Clofent J; Hinojosa J
Gastroenterol Hepatol; 2011; 34(7):511-3. PubMed ID: 21737181
[No Abstract] [Full Text] [Related]
4. [Disseminated tuberculosis following infliximab therapy for Crohn disease: a case report].
Bouchentouf R; Yasser Z; Aitbenasser MA
Rev Pneumol Clin; 2014 Dec; 70(6):366-9. PubMed ID: 25131370
[TBL] [Abstract][Full Text] [Related]
5. [Bone and joint tuberculosis concurrent with tuberculosis of other organs].
Yagi O; Kawabe Y; Nagayama N; Shimada M; Kawashima M; Kaneko Y; Ariga H; Ohshima N; Matsui Y; Suzuki J; Masuda K; Tamura A; Nagai H; Akagawa S; Machida K; Kurashima A; Nakajima Y; Yotsumoto H
Kekkaku; 2007 Jun; 82(6):523-9. PubMed ID: 17633120
[TBL] [Abstract][Full Text] [Related]
6. Use of steroids to treat anti-tumor necrosis factor α induced tuberculosis-associated immune reconstitution inflammatory syndrome: Case report and literature review.
Nabeya D; Kinjo T; Yamaniha K; Yamazato S; Tome R; Miyagi K; Nakamura H; Kinjo T; Haranaga S; Higa F; Fujita J
Medicine (Baltimore); 2020 Oct; 99(43):e22076. PubMed ID: 33120729
[TBL] [Abstract][Full Text] [Related]
7. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
[TBL] [Abstract][Full Text] [Related]
8. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
Lawrance IC; Radford-Smith GL; Bampton PA; Andrews JM; Tan PK; Croft A; Gearry RB; Florin TH
J Gastroenterol Hepatol; 2010 Nov; 25(11):1732-8. PubMed ID: 21039834
[TBL] [Abstract][Full Text] [Related]
9. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
Sandborn WJ; Hanauer SB
Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177
[TBL] [Abstract][Full Text] [Related]
10. [Tuberculosis in compromised hosts].
Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
[TBL] [Abstract][Full Text] [Related]
11. [Fatal miliary tuberculosis following treatment with Infliximab].
Karoui S; Bouallegue L; Hamzaoui S; Filali A; Boubaker J
Tunis Med; 2004 Apr; 82(4):393-6. PubMed ID: 15453039
[TBL] [Abstract][Full Text] [Related]
12. Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report.
Malaviya AN; Kapoor S; Garg S; Rawat R; Shankar S; Nagpal S; Khanna D; Furst DE
J Rheumatol; 2009 Jul; 36(7):1414-20. PubMed ID: 19487263
[TBL] [Abstract][Full Text] [Related]
13. How to improve the safety of biologic therapy in Crohn's disease.
Ferkolj I
J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():67-70. PubMed ID: 20388947
[TBL] [Abstract][Full Text] [Related]
14. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease.
Theis VS; Rhodes JM
Aliment Pharmacol Ther; 2008 Jan; 27(1):19-30. PubMed ID: 17944997
[TBL] [Abstract][Full Text] [Related]
15. Life-threatening disseminated tuberculosis as a complication of treatment by infliximab for Crohn's disease: report of two cases, including cerebral tuberculomas and miliary tuberculosis.
Tissot C; Couraud S; Meng L; Girard P; Avrillon V; Gérinière L; Perrot E; Souquet PJ
J Crohns Colitis; 2012 Oct; 6(9):946-9. PubMed ID: 22749231
[TBL] [Abstract][Full Text] [Related]
16. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome of Crohn's disease treated with infliximab.
Arslan S; Kav T; Besisik F; Kaymakoglu S; Pinarbasi B; Tözün N; Hamzaoglu HO; Duman D; Ulker A; Parlak E; Palabiyikoglu M; Dökmeci A
Hepatogastroenterology; 2003; 50(52):952-6. PubMed ID: 12845957
[TBL] [Abstract][Full Text] [Related]
18. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis.
Esteve M; Saro C; González-Huix F; Suarez F; Forné M; Viver JM
Gut; 2004 Sep; 53(9):1363-5. PubMed ID: 15306601
[TBL] [Abstract][Full Text] [Related]
19. [A case of acute and necrotizing cutaneous Mycobacterium marinum infection in a patient treated with infliximab for Crohn's disease].
Guyot A; Begon E; Abramowitz L; Landry J; Marinho E; Descamps V; Crickx B
Ann Dermatol Venereol; 2009 Nov; 136(11):806-10. PubMed ID: 19917434
[TBL] [Abstract][Full Text] [Related]
20. Infliximab (Remicade), a new biological treatment for Crohn's disease.
D'Haens GR
Ital J Gastroenterol Hepatol; 1999; 31(6):519-20. PubMed ID: 10575573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
